Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 13/20 | 0.68 |
| ▸ | CCND1 | P24385 | 12/20 | 0.68 |
| ▸ | CCND2 | P30279 | 12/20 | 0.68 |
| ▸ | CCND3 | P30281 | 12/20 | 0.68 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.60 |
| ▸ | CDK2 | P24941 | 3/20 | 0.60 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.60 |
| ▸ | PAK4 | O96013 | 1/20 | 0.60 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.60 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.60 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.59 |
| ▸ | CDK1 | P06493 | 2/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.59 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.59 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.59 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.59 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.59 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10192679 | 0.88 | CDK4 (0.73) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL12676578 | 0.87 | CDK4 (0.72) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL659547 | 0.87 | CDK4 (0.72) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL10192660 | 0.87 | CDK4 (0.72) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL10192671 | 0.87 | CDK4 (0.72) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL10192740 | 0.87 | CDK4 (0.64) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL10192732 | 0.87 | CDK4 (0.64) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL10192713 | 0.86 | CDK4 (0.70) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL9988786 | 0.86 | CDK4 (0.67) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL10192667 | 0.85 | CDK4 (0.69) | CDK4CCND1CCND2CCND3CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120270844-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270844-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270844-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | PSEN2, MAPT, PSEN1 | CDK4 2592/4885CCND1 4850/4885CCND2 4797/4885 |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | PAK2, PAK3, PAK4 | CDK4 2735/4885CCND1 4872/4885CCND2 4839/4885 |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | CDK4 1028/4885CCND1 4465/4885CCND2 4323/4885 |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | SMN1; SMN2, PYGB, PMP22 | CDK4 2822/4885CCND1 4884/4885CCND2 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.